Research Topics
Species | Shankar VallabhajosulaSummaryAffiliation: Cornell University Country: USA Publications
| Collaborators
|
Detail Information
Publications
(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localizationShankar Vallabhajosula
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Cornell University, New York, NY 10021, USA
Semin Nucl Med 37:400-19. 2007..The potential routine clinical utility of (18)F-labeled PET radiopharmaceuticals depends also on regulatory compliance in addition to documentation of potential safety and efficacy by various investigators...- Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factorsShankar Vallabhajosula
Department of Radiology, Weill Cornell Medical College of Cornell University, Nuclear Medicine, STARR 221, New York, NY 10065, USA
Semin Nucl Med 40:220-41. 2010..This review provides a comprehensive summary of various factors and specific examples to illustrate the significance of altered biodistribution of radiopharmaceuticals... - Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 E 68th Street, STARR 221, New York, NY 10021, USA
J Nucl Med 46:850-8. 2005.... - Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, New York, USA
J Nucl Med 46:634-41. 2005..The radiation dosimetry of 90Y-J591 was estimated based on both 111In and 177Lu data to validate the usage of 111In as a chemical and biologic surrogate for 90Y... - Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacologyShankar Vallabhajosula
Department of Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA
Semin Nucl Med 41:324-33. 2011..The very high SA of n.c.a. [(131)I]MIBG drug would increase the specific cellular uptake of adrenergic neurons and neuroendocrine tumor cells expressing NET... - Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloidShankar Vallabhajosula
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Weill Cornell Medical College of Cornell University and New York Presbyterian Hospital, NY, USA
Semin Nucl Med 41:283-99. 2011..In addition, PET amyloid imaging will also help test the amyloid cascade hypothesis of AD and as an aid to assess the efficacy of antiamyloid therapeutics currently under development in clinical trials... - Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude miceShankar Vallabhajosula
Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
Prostate 58:145-55. 2004..Radiolabeled J591 monoclonal antibody (MAb) binds with high affinity to an extracellular epitope of PSMA and localizes specifically in PSMA positive LNCaP tumors in vivo... - A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?Shankar Vallabhajosula
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Weill Cornell Medical College of Cornell University and New York Presbyterian Hospital, USA
Semin Nucl Med 41:246-64. 2011..This review briefly describes the chemistry, mechanisms(s) of localization, and clinical application of both proprietary and nonproprietary new PET drugs under multicenter clinical evaluation... - Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicityShankar Vallabhajosula
Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
Clin Cancer Res 11:7195s-7200s. 2005..Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose. We have studied the effect of two or three treatments of 177Lu-J591 and 90Y-J591 monoclonal antibodies (mAb) on myelotoxicity... - Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumorPeter M Smith-Jones
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY 10021, USA
J Nucl Med 44:610-7. 2003..In addition, because J591 and J415 mAbs are specific to PSMA(ext), thus targeting viable tumor, these immunoconjugates are better candidates for targeted radioimmunotherapy than are antibodies targeting PSMA(int)... - Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones
Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Lymphoma 48:342-8. 2007..Two patients had objective responses of 1 and 42.4+ months, respectively. RIT with attenuated dose iodine 131 tositumomab for patients with >25% BMI has acceptable toxicity and can result in lymphoma responses... - Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander
Department of Urology, Division of Nuclear Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY 10021, USA
J Urol 170:1717-21. 2003.... - Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik
Center for Lymphoma and Myeloma, Division of Hematology/Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
Cancer 106:616-22. 2006..CONCLUSIONS: Most patients with progressive disease after treatment with iodine I-131 tositumomab were able to receive subsequent therapy, including cytotoxic chemotherapy and stem cell transplantation... - Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancerNeil H Bander
Department of Urology, Weill Medical College of Cornell University, 525 E 68th St, E 300, New York, NY 10021, USA
J Clin Oncol 23:4591-601. 2005.... - Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York 10021, USA
J Clin Oncol 25:540-7. 2007..This was a proof-of-principle evaluation of PSMA as a potential neovascular target. The primary end points were targeting,toxicity, maximum-tolerated dose, pharmacokinetics (PK), and human antihuman antibody (HAHA) response... - Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa
Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA
Cancer 116:1075-83. 2010..Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti-PSMA radioimmunotherapy... - PET imaging of leptin biodistribution and metabolism in rodents and primatesGiovanni Ceccarini
Laboratory of Molecular Genetics, Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA
Cell Metab 10:148-59. 2009.... - The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao
James Buchanan Brady Department of Urology, The New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Urol Oncol 20:211-8. 2002..Radioimmunoscintigraphy with this immunoconjugate has demonstrated excellent tumor targeting of prostate cancer sites not only in soft tissue but also in bone... - Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?Shota Konishi
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA
Cancer Biother Radiopharm 19:706-15. 2004..The alternate method, based on a fixed antigen concentration, appears to be practical and may provide a more reliable measure of immunoreactivity... - Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerMatthew I Milowsky
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Clin Oncol 22:2522-31. 2004..5 mCi/m(2). Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation of (90)Y-J591 in the treatment of patients with PC... - Clinical utility of radiolabeled monoclonal antibodies in prostate cancerKevin A David
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Genitourin Cancer 4:249-56. 2006..Additional studies are under way to better define the activity of radiolabeled antibody therapy as well as the role for fractionated therapy and combination approaches with taxane-based chemotherapy... - Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parentsLisa Mosconi
Department of Psychiatry, New York University School of Medicine, New York, NY, USA Electronic address
Neurobiol Aging 34:22-34. 2013..NH and ≥ 71% for MH vs. PH, with relative risk = 1.9-5.1 (p values < 0.005). NL individuals with AD-affected mothers show co-occurring Aβ increases and hypometabolism in AD-vulnerable regions, suggesting an increased risk for AD... - Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's diseaseLisa Mosconi
New York University School of Medicine, New York, NY 10016, USA
Neurobiol Aging 33:624.e1-9. 2012..There were no associations between paternal age and metabolism in any group. Evidence for a maternally inherited, maternal age-related mechanism provides further insight on risk factors and genetic transmission in late-onset AD... - Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applicationsStanley J Goldsmith
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Nucl Med 39:2-10. 2009..In this work, we review the features of each of these agents and discuss the issues involved in their use as radiopharmaceuticals for the identification of inflammation and/or infection... - Site-specific (18)F-labeling of the protein hormone leptin using a general two-step ligation procedureRobert R Flavell
Laboratory of Synthetic Protein Chemistry, Laboratory of Molecular Genetics, Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10065, USA
J Am Chem Soc 130:9106-12. 2008..These protocols will allow for the routine production of site-specifically (18)F radiolabeled leptin, as well as other proteins, for use in PET imaging in systems from mouse to man... - Investigation of the role of the base in the synthesis of [18F]FLTMakiko Suehiro
Citigroup Biomedical Imaging Center, Weill Medical College of Cornell University, 516 East 72nd Street, New York, NY 10021, USA
Appl Radiat Isot 65:1350-8. 2007..When the precursor-to-base ratio was optimal, an overall [18F]FLT yield of 30-40% was achieved even if the precursor amount was as small as 8-13 mg... - Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphomaLale Kostakoglu
Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 94:879-88. 2002.... - Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Bldg Rm 340, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
J Clin Oncol 23:5696-704. 2005..To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma... - Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaJohn P Leonard
Department of Medicine, Division of Hematology Oncology, Weill Cornell Medical College, New York, NY, USA
Blood 119:4597-607. 2012..This study is registered at www.clinicaltrials.gov under identifier NCT00420056... - Early assessment of radiation response using a novel functional imaging modality -- [18F]fluorocholine PET (FCH-PET): a pilot studyBhupesh Parashar
Stich Radiation Center, Weill Cornell Medical College, New York, New York 10065, USA Department of Nuclear Medicine, Weill Cornell Medical College, New York, New York 10065, USA
Discov Med 14:13-20. 2012..The results showed a difference between NR and PR, between NR and CR, and a trend towards significance (p=0.06). Conclusion: FCH-PET scan demonstrated changes in SUVmax during RT that were predictive of final outcome... - Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer'sLisa Mosconi
New York University School of Medicine, New York, NY 10016, USA
Proc Natl Acad Sci U S A 107:5949-54. 2010..Present findings may motivate further research on familial transmission and parent-of-origin effects in LOAD... - Possible axonal regrowth in late recovery from the minimally conscious stateHenning U Voss
Citigroup Biomedical Imaging Center and Department of Radiology, Weill Medical College of Cornell University, and NeuroOncology Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Clin Invest 116:2005-11. 2006..We propose that axonal regrowth may underlie these findings and provide a biological mechanism for late recovery. Our results are discussed in the context of recent experimental studies that support this inference... - Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse modelRobert M Sharkey
Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Ave, Belleville, NJ 07109, USA
Radiology 246:497-507. 2008..To prospectively determine if a bispecific monoclonal antibody (MoAb) pretargeting method with a radiolabeled hapten peptide can depict small (<0.3 mm in diameter) microdisseminated human colon cancer colonies in the lungs of nude mice...